| Osteoporosis |
1 |
1 |
| Bisphosphonate |
0 |
0.99 |
| Clinical Guidelines |
0 |
0.98 |
| Fractures |
0 |
0.51 |
| Bone |
0 |
0.37 |
| Spinal Fractures and Dislocations |
0 |
0.36 |
| Bone Density |
0 |
0.35 |
| Osteopenia |
0 |
0.13 |
| Estrogen |
0 |
0.1 |
| Primary Osteoporosis |
0 |
0.1 |
| Vertebral Fracture |
0 |
0.08 |
| Low Testosterone |
0 |
0.06 |
| Parathyroid |
0 |
0.05 |
| Testosterone |
0 |
0.05 |
| Adherence |
0 |
0.03 |
| Adverse Effects |
0 |
0.03 |
| Blood |
0 |
0.03 |
| Calcium |
0 |
0.03 |
| Cancer |
0 |
0.03 |
| Clinical Research |
0 |
0.03 |
| Drug Interaction |
0 |
0.03 |
| Exercise |
0 |
0.03 |
| Generics |
0 |
0.03 |
| Insurance |
0 |
0.03 |
| Intravenous |
0 |
0.03 |
| Jaw |
0 |
0.03 |
| Minerals |
0 |
0.03 |
| Oregon |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Transgender |
0 |
0.03 |
| Vitamin |
0 |
0.03 |
| Washington |
0 |
0.03 |
| Healthcare and Medical Technology |
0 |
0.02 |
| Hypogonadism |
0 |
0.02 |
| Neuroendocrine Tumor |
0 |
0.02 |
| Osteoarthritis |
0 |
0.02 |
| Patient Safety |
0 |
0.02 |
| Revenue and Practice Management |
0 |
0.02 |
| Social Determinants of Health |
0 |
0.02 |